Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 515

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 515
---
 cash flow modeling inputs based on assumptions).

Earnings
per Share

Earnings
(loss) per share is computed in accordance with ASC Topic 260, “Earnings per Share” Basic weighted-average number of
shares of common stock outstanding for the year ended December 31, 2024 and December 31, 2023 include the shares of the Company
issued and outstanding during such period, on a weighted average basis. The basic weighted average number of shares of common stock
outstanding excludes common stock equivalents such as stock options and warrants, while diluted weighted average number of shares
outstanding includes such stock options and warrants. As of December 31, 2024 there were 2,814,057
stock warrants and 2,352,670
stock options that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect. As of December 31, 2023 there was 2,774,057
stock warrants that were not included in the computation of diluted earnings per share, because to do so would have an antidilutive
effect.

Note
2. Going Concern

The
accompanying financial statements have been prepared assuming the Company will continue as a going concern which contemplates the realization
of assets and settlement of liabilities and commitments in the normal course of business.

As
of December 31, 2024, the Company had cash of approximately $1.3
million. The Company raised approximately $6.9 million in 2024 and used approximately $5.1
million of cash in operations during the year ended December 31, 2024, had a net loss of $16.5 million in 2024 and had stockholders’ equity of approximately $0.6
million at December 31, 2024, versus stockholders’ equity of approximately $3.4
million at December 31, 2023.

Historically,
the Company has been primarily engaged in developing Telomir-1. During these activities, the Company sustained substantial losses. The
Company’s ability to fund ongoing operations and future clinical trials required for FDA approval is dependent on the Company’s
ability to obtain significant additional external funding in the near term. Since inception, the Company has financed its operations
through related party financings-see Note 4 and an initial public offering – see Note 1. Additional sources of financing may be
sought by the Company. However, there can be no assurance